Lasa Supergenerics Board Meeting on Nov 14 to Approve Q2 Results

Lasa Supergenerics Ltd has announced a Board of Directors meeting scheduled for November 14, 2026. The primary agenda is to consider and approve the unaudited financial results for the quarter and half-year ended September 30, 2026, along with the auditor's limited review report. The trading window will remain closed until 48 hours after the declaration of these results, in compliance with SEBI regulations.